Neither psilocybin nor MDMA is rescheduled under the Controlled Substances Act before December 31, 2026.

The U.S. government will not officially move psilocybin or MDMA to a less-restricted legal category before the end of 2026. This matters because it means people can't legally use these drugs for therapy anywhere in America, and companies can't sell them, no matter what state you live in.

DEA rescheduling requires agency concurrence and completion of a formal comment and review period—a process that takes 12–24 months minimum once initiated. No active rescheduling petition for either substance is at final-rule stage as of June 2026. DEA has signaled willingness to use procedural tools to delay. Without FDA approval of an MDMA NDA (itself unlikely this year), the automatic DEA scheduling trigger does not activate. This prediction is independently falsifiable: a Federal Register final rule would constitute resolution.